ArticleLife (Basel, Switzerland)2025
Network Analysis of Predicted Therapeutic Symptoms in National Health Insurance Herbal Prescriptions.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances and Perspectives in Terms of the Therapeutic Effects of Natural Products on Human Diseases.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundNational Health Insurance Herbal prescriptions (NHPs) are widely used; however, their multi-component composition complicates mechanistic interpretation and impedes the development of evidence-based approaches in traditional medicine and healthcare policy. In this study, we applied a systems biology approach to link molecular mechanisms to clinical effects.
methodsFrom 56 NHPs, 13 with sufficient clinical evidence were selected. Multi-layer networks connecting herbs, ingredients, genes, and diseases were constructed using SymMap, with interactions filtered for oral bioavailability and statistical significance (false discovery rate < 0.05). Network-predicted diseases were validated against a clinically validated benchmark using permutation-based null model analysis, and gene set enrichment analysis (GSEA) was used to identify key molecular pathways.
resultsNetworks predicted an average of 1359 diseases per NHP, reflecting their polypharmacology. Importantly, the overall predicted disease sets for 10 of 13 NHPs showed statistically significant overlap with known clinical uses (
conclusionsNHPs act as potential systemic homeostasis regulators. Our study introduces a computationally validated framework integrating network pharmacology with permutation-based statistical testing, providing a data-driven rationale for NHP use. These computational findings are exploratory and require future biological and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.